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Psoriasis vulgaris is a chronic inflammatory skin condition, associated with both a
physical and a psychological burden. Our understanding of the etiology of this disease
remains incomplete. Conventionally, psoriasis has been viewed as a condition that
manifests solely in the skin. However, the systemic inflammatory nature of this disease
has been confirmed by the presence of a wide array of dysregulated cytokines and
inflammatory markers in the serum of these patients. Both dysregulated gut and skin
microbiomes have been found in association with psoriasis. An evident association
also exists between inflammatory bowel disease and this condition. Regarding the skin
microbiome, changes have been observed in the relative abundance of Firmicutes,
Actinobacteria, and Proteobacteria. Additionally, Staphylococcus and Streptococcus
spp. were detected more frequently in lesional skin. Alterations in the gut microbiome
have been characterized by a decrease in the Bacteroidetes phylum and an increase in
the Faecalibacterium genus. We suggest that dysbiosis of the skin and gut microbiota
may contribute to psoriasis, by promoting the translocation of microbes from these sites
into the bloodstream. Consistent with the Iron Dysregulation and Dormant Microbes
hypothesis, these microorganisms are in a physiologically dormant state, but may be
awakened periodically and shed their cell wall components, such as lipopolysaccharide
and lipoteichoic acid. Both of these inflammagens may contribute significantly to
maintaining a chronic inflammatory state in the host, such as is seen in individuals
diagnosed with psoriasis.
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INTRODUCTION
Psoriasis is a non-communicable, chronic inflammatory skin condition, which causes the rapid
proliferation of skin cells, forming plaques of thickened skin covered in scales. According to the
global report on psoriasis by the World Health Organization, this disease affects approximately
100 million individuals worldwide (WHO, 2016). We have argued previously (reviewed in Kell
and Pretorius, 2018), that most of these chronic inflammatory diseases share significant elements
in their etiologies. Thus various comorbidities are associated with this condition (Nestle et al.,
2009; Boehncke and Schön, 2015; Kell and Pretorius, 2015b; Brooks, 2018). Psoriasis considerably
impairs patients’ quality of life and may also contribute to psychological stress in a multitude of
these patients (Langley et al., 2005; Nestle et al., 2009). Psoriasis vulgaris (PV), or chronic plaque
psoriasis, is the most common clinical variant and is the focus of this paper, where we will review
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literature that delineates the systemic inflammatory nature of
this condition. Specifically, we aim to emphasize changes in
the gut and skin microbiome associated with PV. We will also
discuss the potential of dysregulated circulating inflammatory
markers with a bacterial origin as a driving force of the chronic
systemic inflammation observed in PV. See Figure 1 for an
overview (and Supplementary Material for notes on the healthy
(normal) microbiome).
THE SYSTEMIC INFLAMMATORY NATURE
OF PV
The etiology of PV is currently not well-understood and
involves a complex interplay between an individual’s genetic
predisposition and environmental factors (Gao et al., 2008; Nestle
et al., 2009; Egeberg et al., 2016). For several years, PV has
been viewed as a condition that is merely “skin-deep,” and thus
inflammation was thought to be limited to the skin. However,
this has been proved untrue in recent years, as new research also
implicates a more general peripheral inflammation in PV.
The basic pathogenesis of PV involves aberrant cross-talk
between the innate and adaptive immune systems, with central
roles for the interleukin-23/interleukin-17 (IL-23/IL-17) axis,
tumor necrosis factor-alpha (TNF-α), and particular skin cells
such as dendritic cells and keratinocytes (Boehncke and Schön,
2015). Briefly, in response to a stressor, such as physical
trauma, dendritic cells in the skin are activated and present
an unknown antigen to naïve T lymphocytes (Ogawa et al.,
2018). Subsequently, activated T lymphocytes differentiate into
type 1 T helper (Th1), type 17 T helper (Th17), and type 22 T
helper (Th22) cells. Dendritic cells, along with macrophages,
B and T lymphocytes, secrete IL-23 which stimulates Th17
cells to differentiate and proliferate (Ogawa et al., 2018). Th17
cells secrete IL-17A, which in turn stimulates keratinocytes to
produce various cytokines and chemokines (Woo et al., 2017;
Ogawa et al., 2018). In addition, IL-23 stimulates the secretion
of IL-22 from Th17 cells, which promotes the hyperproliferation
of keratinocytes (Boehncke and Schön, 2015; Ogawa et al.,
2018). Dendritic cells and Th17 cells also secrete TNF-α,
which activates the nuclear factor-kappa B (NF-κB) signaling
pathway (Nelson, 2004; Ashall et al., 2009; Boehncke and Schön,
2015; Ogawa et al., 2018). These dysregulated inflammatory
molecules necessarily circulate through the cardiovascular
system, accounting for the systemic inflammatory profile of
these individuals. Other dysregulated markers may include, C-
reactive protein, fibrinogen, interferon (IFN)-α, IFN-γ, IL-2, IL-
6, IL-8, IL-12, IL-15, and IL-18 (Arican et al., 2005; Rashmi
et al., 2009; Bai et al., 2018). These inflammatory molecules
may contribute to the development of comorbid diseases. TNF-
α specifically, is implicated in the pathogenesis of both PV
and atherosclerosis. It has been found that TNF inhibitors
have positive effects on cardiovascular biomarkers (Famenini
et al., 2014). PV may also promote the development of type
II diabetes mellitus (T2DM), due to the complex interactions
between adipokines and pro-inflammatory cytokines associated
with PV (Fitzgerald et al., 2014). Particularly, IL-6, IL-8, IL-17,
IL-18, and TNF-α may contribute to the development of insulin
resistance (Fitzgerald et al., 2014). Moreover, TNF-α inhibitors
were positively associated with insulin sensitivity in psoriatic
individuals with T2DM (Al-Mutairi and Shabaan, 2016). A
link also exists between depression and PV. Elevated levels of
cytokines may influence the development of depression and IL-6
appears to play a prominent role (Koo et al., 2017).
THE DRIVING FORCE OF SYSTEMIC
INFLAMMATION IN PV: AN ABERRANT
GUT/SKIN MICROBIOME?
The human microbiome displays a high degree of variation
at inter- and intrapersonal level (Costello et al., 2009).
Consequently, it has been impossible to define a “healthy”
microbiome (Dave et al., 2012). However, it has become apparent
that certain compositions of microbes may promote both
health and disease (Blum, 2017). The term “dysbiosis” refers to
alterations in the composition of the microbiota and has been
implicated in the etiology of various diseases (de Oliveira et al.,
2017; Kell and Pretorius, 2018; Kho and Lal, 2018).
Dysbiosis of both the gut and skin microbiome has been
associated with psoriasis (Gao et al., 2008; Cohen et al., 2009;
Fahlén et al., 2012; Alekseyenko et al., 2013; Li et al., 2013; Scher
et al., 2015; Egeberg et al., 2016; Eppinga et al., 2016; Tett et al.,
2017; Codoñer et al., 2018). Additionally, dysbiosis of the gut
microbiota may contribute to the development of a leaky gut,
facilitating bacterial translocation, which may act as a driving
force of the inflammatory response (Mu et al., 2017). This is
due to the shedding of functionally significant inflammagens,
such as lipopolysaccharide (LPS) and lipoteichoic acid (LTA),
by Gram-negative and Gram-positive bacteria, respectively (Kell
and Pretorius, 2018). Furthermore, evidence is accumulating that
suggests a link between the gut and skin, namely the gut-skin axis.
It may be possible that dysbiosis of the gut microbiome may alter
systemic immunity, resulting in dyshomeostasis and impaired
functioning of the skin (Vaughn et al., 2017; Salem et al., 2018).
GUT DYSBIOSIS
It is well-established that gut dysbiosis co-presents with psoriasis
(Cohen et al., 2009; Li et al., 2013; Scher et al., 2015; Egeberg et al.,
2016; Eppinga et al., 2016; Codoñer et al., 2018). There is also a
significant association between psoriasis and inflammatory bowel
disease (IBD) and immune-related clinical conditions including
those affecting the gastrointestinal tract; and in fact, treatments
for psoriasis are also used for IBD (Pietrzak et al., 2017; Whitlock
et al., 2018).
However, very few studies have characterized alterations in
the composition of the gut microbiome of psoriatic individuals.
Scher et al. (2015) evaluated the relative changes in the gut
microbiome of patients with psoriasis of the skin (PS) as
well as patients with psoriatic arthritis (PA), compared to
control subjects. A significant decrease in microbial diversity was
observed in PS and PA patients (p < 0.05) (Scher et al., 2015).
Indeed, a loss of gut microbial diversity is associated with an array
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FIGURE 1 | An overview of this paper. (1) The etiology of PV involves complex interplay between genetic and environmental factors. (2) This disease displays localized
as well as systemic inflammation, reflected by the presence of various dysregulated inflammatory markers. (3) Dysbiosis of both the gut and skin microbiome are
suggested as possible drivers of chronic systemic inflammation, (4) by facilitating the translocation of bacteria from these sites into systemic circulation. IL, interleukin;
IFN-γ, interferon-gamma; TNF-α, tumor necrosis factor-alpha.
of human diseases (Mosca et al., 2016). In PS patients, the relative
abundance of the Actinobacteria and Bacteroidetes phylyms were
reduced (p < 0.05), while Coprobacillus, Ruminococcus, and
Parabacteroides were decreased at the genus level (Scher et al.,
2015). Similar results were obtained by Codoñer et al. (2018),
who found Bacteroides (a genus belonging to Bacteroidetes) to be
decreased. Bacteroides is known to play an immunomodulatory
role in the gut through the production of polysaccharide A
which activates regulatory T cells (Mosca et al., 2016). Therefore,
a decrease in this genus may result in an altered immune
response to gut microbiota, further contributing to dysbiosis.
Codoñer et al. also revealed the existence of a core microbiome
in PV, which differed from that of healthy individuals (Codoñer
et al., 2018). The psoriatic microbiome was characterized by an
increase in the abundance of Faecalibacterium and a decrease
in Bacteroides spp. Furthermore, Eppinga et al. (2016) found
that a similar dysbiosis occurs in the gut microbiome in both
IBD and psoriasis patients. The study compared the abundance
of Faecalibacterium prausnitzii and Escherichia coli in patients
with psoriasis (including PV, guttate psoriasis and palmoplantaris
pustulosis) and patients with both psoriasis and IBD (CD,
Crohn’s disease and UC, ulcerative colitis ) to controls (Eppinga
et al., 2016). The authors reported a decrease in the beneficial
Faecalibacterium praunitzii in PV (p < 0.001) and IBD (p
< 0.001). The abundance of Faecalibacterium praunitzii was
reduced to a greater extent in patients with both IBD and
psoriasis, when compared to patients with only one of the
conditions. These species produce butyrate, which inhibits the
NF-κB pathway, thereby inhibiting the inflammatory response
(Hiippala et al., 2018). A significant increase was also observed
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in the relative abundance of Escherichia coli in psoriasis patients
(p = 0.002), as well as in patients with concomitant IBD and
psoriasis (p < 0.001).
IBD has been associated with psoriasis since the 1970s
(Verbov, 1973; Yates et al., 1982; Lee et al., 1990). However,
this association has largely been disregarded. Initial reports of
the association between psoriasis and CD, as well as UC, were
confirmed by Cohen et al. (2009). The study cohort comprised
12,502 patients and 24,285 control subjects (Cohen et al., 2009).
The prevalence of CD (0.5%) was significantly increased in
individuals diagnosed with psoriasis, when compared to controls
(0.2%) (p < 0.001). Similarly, a higher prevalence of UC was
observed in patients with psoriasis (0.5%) than the general
population (0.3%) (p = 0.002). Li et al. (2013) aimed to ascertain
the association between the incidence of CD and UC, and
psoriasis in a US population of women. Data were obtained
from 174,476 women. The authors reported that although the
incident risk was increased for CD, this was not the case for
UC (Li et al., 2013). Patients with psoriasis exhibited a greater
risk for the development of CD with a relative risk of 3.86
(95% confidence interval). Furthermore, the risk of developing
IBD after the onset of psoriasis was also evaluated by Egeberg
et al. (2016) in a Danish population. The study included a
total of 5,554,100 subjects. The authors reported a significant
increase in the risk for CD in patients with mild psoriasis,
while a 2- and 3-fold increase in the risk was observed in
severe psoriasis and psoriatic arthritis, respectively (Egeberg
et al., 2016). Comparable results were obtained when psoriasis
and UC was considered. Although none of these studies was
able to determine causality, due to being observational, it is
apparent that an association does indeed exist between PV
and IBD.
SKIN DYSBIOSIS
Dysbiosis of the skin microbiome in individuals diagnosed with
psoriasis has become a recurrent theme. However, recent studies
describing the relative changes in microbial communities are
limited (Gao et al., 2008; Fahlén et al., 2012; Alekseyenko et al.,
2013; Tett et al., 2017). In a seminal study by Gao et al. (2008) the
composition of the skin microbiome in lesional skin of patients
with psoriasis was compared to uninvolved skin of the same
patient as well as control subjects. The authors reported that all
skin types were characterized by the presence of three phyla,
namely Actinobacteria, Firmicutes, and Proteobacteria. Similar
findings have been reported by other studies (Fahlén et al., 2012;
Alekseyenko et al., 2013). Gao et al. (2008) also reported greater
diversity in lesional skin than in uninvolved or healthy skin. In
contrast, three other studies observed a trend toward decreased
diversity in lesional skin (Fahlén et al., 2012; Alekseyenko et al.,
2013). This latter observation is in accordance with literature,
as it has been suggested that decreased diversity of the skin
microbiome is associated with unhealthy skin (Wallen-Russell
and Wallen-Russell, 2017; Dréno et al., 2018).
At the phylum level, an increase in the relative abundance
of Firmicutes has been found in psoriatic skin (Gao et al.,
2008; Alekseyenko et al., 2013). However, discrepant results have
been obtained with regards to the abundance of Actinobacteria
and Proteobacteria. Gao et al. (2008) observed a decrease in
Proteobacteria (p < 0.001) and Actinobacteria (p < 0.01) in
lesional skin. However, another study found that Proteobacteria
were more abundant in lesional skin of the trunk (p =
0.011), while Actinobacteria were underrepresented in affected
skin compared to healthy skin (p = 0.034) (Fahlén et al.,
2012). Additionally, Alekseyenko et al. (2013) identified two
cutaneotypes in their study cohort, where lesional skin was
associated with the cutaneotype characterized by a higher
abundance of Actinobacteria and Firmicutes (p < 0.01). At
the genus level, Streptococcus (p < 0.001) and Staphylococcus
have been found to be more abundant in lesional skin by
Gao et al. Additionally, Fahlén and co-workers observed that
the abundance of Streptococcus spp. were increased in affected
skin, while Staphylococcus were detected more frequently in
the skin of controls (Fahlén et al., 2012). In contrast, Tett
et al. found Staphylococcus to be significantly increased in
lesional skin (p = 0.043). A role for particularly Staphylococcus
aureus and Streptococcus pyogenes has been proposed in
the pathogenesis of PV (Tomi et al., 2005; Weisenseel and
Prinz, 2005; Fry and Baker, 2007). Moreover, Alekseyenko
et al. (2013) observed that the combined relative abundance
of the Gram-positive Corynebacterium, Propionibacterium,
Staphylococcus, and Streptococcus was increased in lesional
skin. In contrast, Gao et al. (2008) found a progressive
underrepresentation of Propionibacterium (p < 0.001) in
affected skin compared to the skin of controls, followed
by unaffected and control skin of individuals diagnosed
with psoriasis. Propionibacterium has been established as
a protective commensal bacteria, as this genus produces
anti-microbial substances and possesses immunomodulatory
properties (Christensen and Brüggemann, 2014). Therefore,
the conflicting results may reflect a disrupted ecology of
the microbiota in psoriasis (underrepresentation), while an
increase may initially be protective (overrepresentation). “Next
generation” whole-genome shotgun-metagenomic sequencing
was utilized for the first time by Tett et al. (2017) to study
microbial communities, as well as changes in the functionality
of these communities in lesional and unaffected skin from PV
patients. The authors emphasized complexities when evaluating
changes in the skin microbiome, as affected skin from different
skin sites exhibited divergent trends, for example at species level,
diversity decreased in lesional skin from the ear (p= 0.008), while
affected skin from the elbow displayed greater diversity.
COULD BACTERIAL TRANSLOCATION VIA
THE GUT OR SKIN PLAY A ROLE IN PV? A
HYPOTHESIS
Blood is commonly regarded as a sterile environment as actively
growing and replicating microbes are considered to be absent
(Damgaard et al., 2015; Kell and Pretorius, 2015a; Potgieter
et al., 2015; Gosiewski et al., 2017). However, dormant or non-
replicating bacteria may be present in the systemic circulation
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(Seubert et al., 2001; Urban et al., 2006; Thwaites and Gant, 2011;
Potgieter et al., 2015; Kell and Pretorius, 2018). These bacteria
do not form colonies when plated directly, have sometimes
been referred to as “unculturable,” and might therefore also
be regarded as non-viable, as classical microbiology equates
viability with culturability (Postgate, 1969; Kell et al., 1998).
However, bacteria in the blood are rather in a physiologically
dormant state, considered to be neither “dead” nor “alive,”
since by definition, dormant organisms can be resuscitated, in
certain cases by particular molecules (Kaprelyants et al., 1993;
Kell and Pretorius, 2015a).
Dysbiosis may promote the translocation of microorganisms
from the gut into the bloodstream in many conditions
(Bischoff et al., 2014; Fukui, 2016; Kell and Pretorius, 2018).
Translocation from the gut may occur via three entry points,
namely dendritic cells, a compromised intestinal epithelial
barrier, and M cells (Potgieter et al., 2015). As mentioned
earlier, these translocating microbes may not be metabolically
active or replicating, yet they may contribute to maintaining a
chronic, low-grade inflammatory state in the host. Periodically,
dormant bacteria may shed their cell wall components, such as
LPS and LTA, especially when awakened (Kell and Pretorius,
2015a; Potgieter et al., 2015). Both of these inflammagens
will induce the production of inflammatory cytokines and
chemokines, activating the innate and adaptive immune systems
(Kell and Pretorius, 2015a, 2018; Potgieter et al., 2015). Our
literature searches strongly suggest a bacterial involvement in PV
(see Table 1).
As discussed above, dysbiosis of both the skin and gut
microbiome is found in association with psoriasis. Therefore,
we hypothesize that dysbiosis of the microbiota in individuals
with PV facilitates the translocation of bacteria from the gut
and skin into the bloodstream, which may act as a driving
force of the chronic, systemic inflammation in these individuals
(Zákostelská et al., 2016). There is some evidence that supports
bacterial translocation in the context of PV. Bacterial DNA
has been detected in monocytes isolated from patients with
PV (Okubo et al., 2002). The authors reported that bacterial
DNA was significantly increased in PV patients, compared to
healthy controls. Munz et al. (2010) also found bacterial DNA in
peripheral blood of patients with guttate psoriasis as well as PV.
Staphylococcus spp. were mainly identified in patients with PV,
while Streptococcus spp. were found in association with guttate
psoriasis (Munz et al., 2010). This last study is of particular
interest, as the relative abundance of these genera is increased in
lesional skin of psoriatic patients (Gao et al., 2008; Fahlén et al.,
2012; Alekseyenko et al., 2013). Moreover, these observations
might suggest the possible translocation of bacteria from the skin
into the bloodstream. Bacterial DNA has also been detected by
Ramírez-Boscá et al. in peripheral blood of patients (p < 0.05)
in their study cohort, with (perhaps surprisingly) Escherichia coli
identified as the main source. Interestingly, bacterial DNA was
not found in patients with guttate and inverse psoriasis. The
authors also reported that cytokine levels correlated significantly
with the presence of bacterial DNA (p < 0.001). This study
proposed the gut as possible origin of these bacteria as most of the
detected species were associated with the intestinal microbiome
(Ramírez-Boscá et al., 2015). A recent study also suggests that the
TABLE 1 | A summary of the most prominent findings that imply a bacterial
component in PV.
Study design Findings References
Administration of benzathine
penicillin in PV patients
(n = 30) for 2 years
Significant improvement
at 12 weeks (p < 0.01)
91–100% improvement
at 2 years (p < 0.01)
Streptococcus
suggested as initial
trigger of guttate
psoriasis, with PV as
delayed manifestation
Saxena and Dogra,
2005
Evaluating levels of
Streptococcus pyogenes
immunoglobulin G
(IgG)-reactive proteins in PV
patients (n = 8) compared
to controls
IgG-reactive proteins
were significantly
increased in patients (p =
0.0009)
El-Rachkidy et al., 2007
Detecting levels of genes
coding for Streptococcal
and Staphylococcal
super-antigens in psoriasis
patients (n = 22)
Super-antigens were
detected in 59% of
patients
El Ferezli et al., 2008
Evaluating the effect of
Streptococcal DNA on
peripheral blood
mononuclear cells (PBMCs)
isolated from PV patients
Enhanced proliferation of
PBMC in patients
(p = 0.032)
Cai et al., 2009
Administration of
azithromycin in PV patients
(n = 30) for 48 weeks
Significant improvement
at 12 weeks
91–100% improvement
in 18 patients and
60–90% improvement in
six patients at 48 weeks
six patients experienced
a relapse after 1 year
Saxena and Dogra,
2010
Determining frequency of
subclinical microbial
infection in PV patients (n =
195) compared to controls
Infection with
Staphylococcus and
Streptococcus were
detected in 68% of
patients, compared to
11% in controls
Bartenjev and
Potocnik, 2000
presence of Prevotella spp. in conjunction with an increase in the
ratio of Faecalibacterium:Bacteroides in the gut of PV patients,
may facilitate bacterial translocation (Codoñer et al., 2018).
From these studies it is evident that bacterial translocation
may take place in PV. However, more research is needed
to determine if bacterial species in the circulation originate
primarily from the gut, the skin or indeed the oral cavity.
Another important aspect would be to determine what specific
changes in the gut and skin microbiome or other external factors
facilitate subsequent bacterial translocation. For instance obesity
is well-known to relate to translocation, and there is significant
association between obesity and psoriasis (Armstrong et al., 2012;
Carrascosa et al., 2014; Jensen and Skov, 2017).
IRON DYSREGULATION
Common to all chronic inflammatory diseases is iron
dysregulation, that can resuscitate dormant microbes (Kell,
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2009; Kell and Pretorius, 2018). Here too there is clear evidence
for the involvement of a deranged iron metabolism (Trenam
et al., 1992; Wojas-Pelc and Marcinkiewicz, 2007). One possible
strategy is thus the use of iron chelators (Hider et al., 1992); see
also Supplementary Material.
IMPLICATIONS FOR TREATMENT
Recently it was also suggested that treatment of psoriasis might
begin with altering the bowel flora toward normality, and therapy
might include the use of appropriate antibiotics (Wang et al.,
2009; Waterhouse et al., 2009; Youssef et al., 2011; Alzolibani and
Zedan, 2012; Baros et al., 2014; Kadam et al., 2015; Zákostelská
et al., 2016; Allen et al., 2017; Ely, 2018). This avenue should be
investigated further. Also, the use of prebiotics might be a useful
avenue to investigate (Ely, 2018). Importantly, an improved
knowledge of the basis for psoriatic lesions is only of real value
if it leads to beneficial therapies. Since our main point here is
that a chief driver is the atopobiotic appearance of unwanted
microbes in these skin lesions, an obvious suggestion is the
use of those antibiotics that can penetrate into host cells via
membrane transporters (Kell et al., 2013; Kell and Oliver, 2014;
Prideaux et al., 2015). This suggestion seems to be borne out in
practice (Saxena and Dogra, 2005, 2010; Walecka et al., 2009).
Finally, if inflammation is a cause and not a manifestation,
one may anticipate that anti-inflammatories might also be of
value (Aggarwal and Harikumar, 2008; Kang et al., 2016; Chen
et al., 2017; Sharma et al., 2017; Kerley et al., 2018; Owczarczyk-
Saczonek et al., 2018).
CONCLUSION
“Coherence” describes the idea that if several independent lines of
evidence lead to a similar conclusion, that conclusion is thereby
strengthened (Thagard, 1999, 2008). Here we have brought
together evidence in order to formulate such a coherence in our
scientific understanding of PV. Specifically, our aim was to bring
together multiple lines of evidence suggesting the role of a leaky
gut, the presence of inflammation and aberrantmicrobiome, both
in the gut and the skin, and how this may be directly linked to
the development of PV. PV is a chronic inflammatory condition
characterized by the hyperproliferation of keratinocytes and
infiltration by immune cells. Aside from inflammation localized
to the skin, this disease also displays systemic inflammation
reflected in the multitude of dysregulated inflammatory markers
in the blood of these individuals. Consequently, there are a
great many comorbidities and other epidemiological data that
give vital clues to their etiologies. An aberrant skin microbiome
has been associated with psoriasis, with specific alterations
in the relative abundance of Firmicutes, Actinobacteria and
Proteobacterium. Additionally, Streptococcus and Staphyloccocus
have been found to be increased in affected skin. Gut dysbiosis,
characterized by a decrease in microbes with anti-inflammatory
and immunomodulatory properties, also seems to be prevalent in
individuals diagnosed with PV.Moreover, an association between
IBD and psoriasis is evident, with both conditions exhibiting a
similar dysbiosis. We suggest that dysbiosis of the skin and gut
microbiota may contribute to PV by facilitating the translocation
of microorganisms into the blood, and that it is indeed worth
considering microbes as etiological agents in this disease.
A question that needs to be further investigated is whether
the changes in gut bacteria in psoriasis patients are a cause or
a result (or both), and how their presence may be managed in a
treatment regime. In particular, microbes may appear where they
should not be present, and may shed inflammagens, such as LPS
and LTA, both of which will result in an inflammatory responses.
Therefore, detailed characterization of the microbiome in PV,
and the use of suitable pro- and anti-biotics may have important
implications in terms of preventing, diagnosing and treating
this disease.
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